Spectrum Pharmaceuticals — Investor Presentation (January 2017)
27 slides from Spectrum Pharmaceuticals's investor presentation, Jan 9, 2017
Slide 1: Spectrum Pharmaceuticals Investor Presentation January 2017
Spectrum Pharmaceuticals Rajesh C. Shrotriya, MD Chairman and Chief Executive Officer Investor Presentation January 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current bel
Slide 3: Spectrum Advancing Three Strong Oncology Focused Drugs
Poziotinib A promising Phase 2 pan-HER inhibitor 3 ROLONTIS TM Late-stage drug targeting blockbuster market QAPZOLA TM Late-stage drug targeting unmet need in bladder cancer Spectrum Advancing Three Strong Oncology Focused Drugs
Slide 4: A Transformative Pipeline Targeting Large Markets
4 ROLONTIS TM (SPI-2012, eflapegrastim) Chemotherapy-Induced Neutropenia 460,398 Patients1 POZIOTINIB Breast Cancer 252,710 Patients2 QAPZOLA TM Bladder Cancer 76,960 Patients 3 587,426 People living with Bladder Cancer3 A Transformative Pipeline Targeting Large Markets 1 Spectrum Physician Market r
Slide 5: ROLONTIS (eflapegrastim): A Long-Acting G-CSF
ROLONTISTM (eflapegrastim): A Long-Acting Granulocyte-Colony Stimulating Factor (G-CSF) 5 • Phase 3
Slide 6: A Novel Drug Being Studied for the Treatment of Neutropenia
GCSF Analog Fc FcRn Flexible PEG Linker LAPS Carrier FcRn Bone Marrow Epithelial Layer A Novel Drug Being Studied for the Treatment of Neutropenia 6
Slide 7: ROLONTIS Phase 2 Efficacy: Median ANC Over Time in Cycle 1
0 5 10 15 20 25 30 35 40 0 5 10 15 20 A N C (1 0 9 /L ) Days ROLONTIS - 270 μg/kg ROLONTIS - 45 μg/kg ROLONTIS - 135 μg/kg pegfilgrastim - 6 mg Study Drug Chemo Therapy 7 ROLONTIS Phase 2 Efficacy Median Absolute Neutrophil Count (ANC) Over Time in Cycle 1
Slide 8: ROLONTIS Phase 2 Primary Endpoint: Days of Severe Neutropenia
Phase 2 met primary endpoint of mean duration of severe neutropenia during cycle one in patients with breast cancer Non-inferiority achieved for ROLONTIS 135 µg/kg and 270 µg/kg arms Superiority achieved for ROLONTIS 270 µg/kg over pegfilgrastim ROLONTIS 45 µg/kg (N=39) ROLONTIS 135 µg/kg (N=3
Slide 9: ROLONTIS Phase 3 Program: Expected to File BLA in 2018
Screening Period End of Treatment Visit 30 Days R a ndomi z atio n Treatment Period Four 21-day Cycles Day 1 Day 2 Pegfilgrastim ROLONTIS (eflapegrastim) Docetaxel + Cyclophosphamide ~30 Days after the end of cycle 4 2 Randomized, Non-inferiority studies with duration of severe neutropenia (DSN) a
Slide 10: Poziotinib: A Novel, pan-HER Inhibitor
Poziotinib: A Novel, pan-HER Inhibitor 10 • Breast Cancer Phase 2 • Non-Small Cell Lung Cancer (NSCLC) Phase 1
Slide 11: Poziotinib: A Novel, pan-HER Inhibitor
Orally available quinazoline compound class Irreversible tyrosine kinase inhibitor of EGFR family of receptors (pan-HER inhibitor) Binds covalently to ATP binding site of EGFR family of tyrosine kinases and inhibits tyrosine kinase activity 11 Poziotinib: A Novel, pan-HER Inhibitor
Slide 12: Poziotinib Phase 1 Study Tumor Responses
Poziotinib Phase 1 Study Tumor Responses Tumor size reductions in heavily pre-treated patients with diverse tumors (NSCLC/breast/gastric cancers) 12
Slide 13: Clinical Data From pan-HER Inhibitors in Breast Cancer
13 Clinical Data From pan-HER Inhibitors in Breast Cancer POZIOTINIB Spectrum/Hanmi Hanmi Aggregate Phase 1: Im S et al. 20151 ORR: 60% (10 patients) Prior treatment with: Trastuzumab Lapatinib Pertuzumab* * One patient treated with prior pertuzumab who had PR Neratinib Puma Biotechnology Phase 2: B
Slide 14: Poziotinib Phase 2 Design in Breast Cancer
Phase 2, Open Label Indication: HER2-positive, recurrent, metastatic breast cancer who have received at least 2 prior HER2-directed treatment regimens. Primary objective is to evaluate the Objective Response Rate (ORR) of poziotinib in patients with human epidermal growth factor receptor 2 (HE
Slide 15: Poziotinib: Promising Activity in Non-Small Cell Lung Cancer
15 Poziotinib: Promising Activity in Non- Small Cell Lung Cancer (NSCLC) Lung cancer is by far the leading cause of cancer death among both men and women, estimated 155,870 deaths in 20171 Existing therapies have very limited activity in NSCLC Exon 20 mutations MD Anderson Cancer Center has sc
Slide 16: Patients with Exon Mutation had Poor Prognosis
16 Patients with Exon 20 Mutation had Poor Prognosis Median PFS EGFR Ex20 insertion (N=9) 2 months Classical EGFR mut (N=129) 14 months 0 10 20 30 40 50 0 20 40 60 80 100 Time (Months) Pr og re ss io n fre e su rv iv al (% o f p at ie nt s) Classical EGFR mutations (n=129) EGFR exon 20 insertions (n
Slide 17: Poziotinib's Unique Structure Appears to Overcome Exon 20 Resistance
0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 EGFR Exon20 Insertion Mutations log[Inhibitor], µM % V ia bi lit y AZD9291 EGF816 CO-1686 Afatinib Erlotinib Poziotinib 0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 EGFR Exon20 Insertion Mutations log[Inhibitor], µM % V ia b il it y AZD9291 EGF816 CO-1686 Afa
Slide 18: Poziotinib Summary
18 Poziotinib Summary Orally available, Irreversible pan- EGFR/HER inhibitor Phase 2 Breast Cancer Study ongoing Investigator sponsored trial of poziotinib and EGFR/HER2 Exon 20 insertions scheduled to begin at MD Anderson Cancer Center in first half of 2017 Hanmi studies in gastric and colo
Slide 19: QAPZOLA (apaziquone) for Intravesical Installation
QAPZOLATM (apaziquone) for Intravesical Installation: A potent tumor-activated drug for non- muscle invasive bladder cancer 19
Slide 20: QAPZOLA Targets Surface Tumors in the Bladder
20 NMIBC Non-muscle invasive bladder cancer remains an unmet medical need with no new drugs approved in the last 25 years QAPZOLA demonstrated activity in previous studies Safety profile shows that QAPZOLA is well-tolerated QAPZOLATM Targets Surface Tumors in the Bladder
Slide 21: Spectrum is in Discussions with FDA on New Study Design for QAPZOLA
21 Spectrum is in Discussions with FDA on New Study Design for QAPZOLA Seeking SPA for proposed Phase 3 study design New study design incorporates learnings from previous studies Study Design • Approximately 500 patients with non-muscle-invasive bladder cancer (NMIBC) • Single dose: 8mg • Intr
Slide 22: Proven Track Record to Pave the Path to the Future
Currently Marketing 6 Niche Anti-Cancer Drugs Contributing to a Pipeline Targeting Large Markets 22 Proven Track Record to Pave the Path to the Future
Slide 23: Spectrum Pharmaceuticals
23 Spectrum Pharmaceuticals Spectrum Pharmaceuticals is a biotechnology Company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology.
Slide 24: Non-GAAP Financial Measures
Non-GAAP Financial Measures ‘non-GAAP financial measures,” as defined in Regulation 1934, Non-Gs differ “GAAP"), ‘Regulation G, we ind bel Therefore, investors ‘or as superior to, measures spared in AAP. The non- man Company may be diffe
Slide 25: Non-GAAP Reconciliation Tables
Three months ended September 30, 2016 Nine months ended September 30, 2016 2016 2015 2016 2015 (1) GAAP product sales, net & license fees and service revenue $ 33,393 $ 28,627 $ 111,208 $ 112,226 Non GAAP adjustments to product sales, net & license fees and service revenue: — — (6,000 ) (9,681 ) Non
Slide 26: Condensed Consolidated Statements of Operations
‘Condensed Consolidated Statements of Operations (nthar ‘Total operating costs and expenses ‘Nine Months Ended ™ytoee se September 30, 2018 2016 ons 2016 $ 96401 $ 102,014 31226 7,503 21,508 2201 = 19,465 19411 65,297 13,293 9924 35,333 6907 6919 27.857 49,389 OL 149,955 G59 06,074) 7.789) 2373) G27
Slide 27: Condensed Consolidated Balance Sheets
SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheets (In thousands, expect per share and par value amounts) (Unaudited) 27
Spectrum Pharmaceuticals — Investor Presentation (January 2017) on 6ix